ACADIA third one fourth revenues decrease to $584.
We look forward to building upon this momentum as we close out the year and attempt what we expect to be an exciting and value-traveling 2012. Revenues totaled $584,000 for the 3rd quarter of 2011 in comparison to $2.3 million for the 3rd quarter of 2010. This decrease was primarily due to the bottom line of ACADIA’s collaboration with Biovail in October 2010. ACADIA regarded $1.7 million in revenues from that collaboration in the 3rd quarter of 2010. Analysis and development expenses reduced to $4.2 million for the 3rd quarter of 2011, including $129,000 in stock-based compensation, from $5.0 million for the 3rd quarter of 2010, including $133,000 in stock-based compensation. This decrease was primarily because of savings in facilities and other costs connected with ACADIA’s analysis and development organization and also lower external assistance costs.After 5 years of follow-up, the meta-analysis didn’t show any significant variations in prices of survival between your PCI and CABG groupings,34 although other research show differences in mortality.10-12 Second, the usage of medication differed between your groups inside our study, reflecting variations in standard care of patients between the two treatment organizations. Third, more sufferers withdrew, after randomization, from the CABG group than from the PCI group. Fourth, although randomization was executed in a blinded way, with individuals and clinicians unaware of future treatment assignments, it was not possible to blind the functionality of the procedure.